235 Antigen presentation pathways prime melanoma patients for more durable response to anti–PD-1 checkpoint blockade therapy

235 Antigen presentation pathways prime melanoma patients for more durable response to anti–PD-1 checkpoint blockade therapy

Bibliographic Details
Main Authors:	Joseph Markowitz, Anders Berglund, Saurabh Garg, Eric Welsh, Bin Fang, Yuliana Hernandez, Trevor Rose, Jhanelle Gray, John Koomen, James Mule
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

Multi-Omics and Informatics Analysis of FFPE Tissues Derived from Melanoma Patients with Long/Short Responses to Anti-PD1 Therapy Reveals Pathways of Response
by: Saurabh K. Garg, et al.
Published: (2020-11-01)

Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma
by: Elena Galvani, et al.
Published: (2020-02-01)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
by: Xin Wang, et al.
Published: (2019-02-01)

300 Transcriptional engineering of CAR T cell memory promotes durable control and synergy with PD-1 checkpoint blockade immunotherapy in solid tumors
by: Surojit Sarkar, et al.
Published: (2023-11-01)

Identification of MicroRNA–mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes
by: Robert A. Szczepaniak Sloane, et al.
Published: (2021-10-01)

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
by: Paolo A. Ascierto, et al.
Published: (2019-03-01)

Bioinformatic analysis of PD-1 checkpoint blockade response in influenza infection
by: Huilin Ou, et al.
Published: (2022-08-01)

The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
by: Firas Y. Kreidieh, et al.
Published: (2023-07-01)

Molecular patterns of resistance to immune checkpoint blockade in melanoma
by: Martin Lauss, et al.
Published: (2024-04-01)

Predictive factors of neoadjuvant immune checkpoint blockade in melanoma
by: Melissa Sarver, et al.
Published: (2022-05-01)

Predictors of responses to immune checkpoint blockade in advanced melanoma
by: N. Jacquelot, et al.
Published: (2017-09-01)

Mutations Associated with No Durable Clinical Benefit to Immune Checkpoint Blockade in Non-S-Cell Lung Cancer
by: Guangsheng Zhu, et al.
Published: (2021-03-01)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
by: Bogang Wu, et al.
Published: (2018-11-01)

Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy
by: Masaki Terabe, et al.
Published: (2017-05-01)

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
by: Mengjie Wang, et al.
Published: (2022-04-01)

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
by: Iris Koopmans, et al.
Published: (2018-08-01)

PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates
by: Yago Pico de Coaña, et al.
Published: (2020-01-01)

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
by: Alice L. Hung, et al.
Published: (2018-08-01)

Durable disease control with local treatment for oligoprogression of metastatic solid tumors treated with immune checkpoint blockade
by: Kunal K. Sindhu, et al.
Published: (2020-01-01)

Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma
by: Jan-Michael Werner, et al.
Published: (2019-02-01)

The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
by: Su Yin Lim, et al.
Published: (2023-03-01)

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
by: Weijie Ma, et al.
Published: (2016-05-01)

LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade
by: Liu, Y, et al.
Published: (2021)

LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade
by: Yi Liu, et al.
Published: (2021-11-01)

Enhanced T-Cell Priming and Improved Anti-Tumor Immunity through Lymphatic Delivery of Checkpoint Blockade Immunotherapy
by: Carolina Mantilla-Rojas, et al.
Published: (2022-04-01)

PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma
by: Joshua W. D. Tobin, et al.
Published: (2021-05-01)

PD-1 Immune Checkpoint Blockade Promotes Therapeutic Cancer Vaccine to Eradicate Lung Cancer
by: Pournima Kadam, et al.
Published: (2020-06-01)

Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy.
by: Janna Krueger, et al.
Published: (2021-01-01)

Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization
by: Yuwei Liu, et al.
Published: (2022-06-01)

PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells
by: Karla M. Viramontes, et al.
Published: (2022-06-01)

Further investigation of blockade effects and binding affinities of selected natural compounds to immune checkpoint PD-1/PD-L1
by: Huifang Li, et al.
Published: (2022-09-01)

Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes
by: Dan Zheng, et al.
Published: (2022-07-01)

A Novel Computational Framework for Predicting the Survival of Cancer Patients With PD-1/PD-L1 Checkpoint Blockade Therapy
by: Xiaofan Su, et al.
Published: (2022-06-01)

Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade
by: Douglas B. Fox, et al.
Published: (2023-03-01)

Research Trends in Immune Checkpoint Blockade for Melanoma: Visualization and Bibliometric Analysis
by: Yantao Xu, et al.
Published: (2022-06-01)

Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma
by: Beckey Trinh, et al.
Published: (2019-02-01)

Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade
by: Elizabeth I. Buchbinder, et al.
Published: (2021-04-01)

Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy
by: Anastasia Prokopi, et al.
Published: (2021-01-01)

Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma
by: Adam L. Burrack, et al.
Published: (2019-08-01)

MCT4 blockade increases the efficacy of immune checkpoint blockade
by: Christian Schmidl, et al.
Published: (2023-10-01)